Author Archives: James Carroll

About James Carroll

Founder and CEO at THOR Photomedicine Ltd. View biography (PDF)

New Technologies, Treatments Can End Opioid Use

Those suffering from America’s opioid crisis recently received two major messages of hope.

On Oct. 24, President Donald Trump signed the Opioid Crisis Response Act (OCRA) into law. Dozens of bills designed to address the diverse aspects of the opioid crisis were consolidated into one strategic and integrated approach.

OCRA received overwhelming bi-partisan support in both Chambers.

HR6, which is now Public Law 115-2716, broke new ground in being the first legislation to mandate aggressive development and adoption of alternative pain treatments that include “innovative medical technologies for pain management.”

On Oct. 11, Congress held its first ever briefing on ending opioid use through … Continue reading

Posted in Industry, THE FUTURE OF LLLT | Leave a comment

LumiThera and Optos Announce Collaboration to Commercialize the Valeda™ Light Delivery System for Treating Dry Age-Related Macular Degeneration in Europe

LumiThera's Valeda® Light Delivery SystemLumiThera Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, announced a distribution agreement with Optos Plc, a division of Nikon, Inc., Japan to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in 12 European countries. Optos is recognized as the leading provider of ultra-widefield retinal imaging devices to eyecare professionals for improved patient eye care. The announcement follows the recent CE Mark Certification for the European Union (EU) for the treatment of dry AMD utilizing LumiThera’s Valeda™ Light Delivery System.

“The Distribution agreement with Optos allows LumiThera to begin commercialization … Continue reading

Posted in Industry | Leave a comment

LumiThera, Inc. to Debut Valeda Light Delivery System at the 18th Congress of the EURETINA

LumiThera LT-300 Light Delivery SystemLumiThera® Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and diseases, announced that it will participate in the combined exhibition of the 18th EURETINA Annual Meeting and the 36th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), held in Vienna, Austria from the 20th to the 26th of September 2018.

EURETINA actively promotes new diagnostic developments, advances in vitreoretinal surgery, the development and application of new drugs, and changes in the treatment of macular degeneration.

LumiThera will debut the Valeda™ Light Delivery System for the treatment of dry AMD in the exhibition hall and will host a … Continue reading

Posted in Industry | Leave a comment

PBM Therapy Literature Watch February 2018

36 Photobiomodulation therapy papers published in February 2018. Highlights include:

  • DNA repair mechanisms, modulation of telomere maintenance
  • Improved motor response in patients with spinal cord injury
  • Prevention of < grade 2 radiodermatitis in breast cancer patients (RCT)
  • No adverse effects on SCC primary cancer, recurrence or survival
  • Improved physiological and performance parameters in runners
  • Improved depth of anaesthesia during endodontic treatment
Posted in Research | Leave a comment

LumiThera LT-300 Device for treating Dry Advanced Macular Degeneration granted CE Mark

LumiThera LT-300 Light Delivery System“The CE mark allows LumiThera to begin commercialization throughout the 28 EU member states and coincides with the initiation of the LIGHTSITE II Clinical Study in select European sites in the upcoming months,” stated Clark Tedford, Ph.D., LumiThera President and CEO. “We are excited to be able to offer a safe and effective early stage clinical intervention for patients with dry AMD.”

“It is very exciting to see the development of PBM treatment for dry AMD patients,” stated Samuel Markowitz, M.D., Department of Ophthalmology and Vision Sciences, University of Toronto. “These patients have limited options and losing their central vision is horribly debilitating to their quality of … Continue reading

Posted in Industry | 2 Comments

PBM Therapy Literature Watch January 2018

27 Photobiomodulation therapy papers published in January 2018. Highlights include:

  • Treatment 6h before + immediately before exercise best for reducing muscle fatigue
  • Review of pre-clinical data for dementia, Parkinson’s, stroke, trauma and depression
  • Improved bacteriological, cytological and clinical benefits after root planing (RCT)
  • Improved wound healing of skin graft donor site (RCT)
  • Systematic review of RCTs on  LED PBM therapy in dermatology
  • NSAIDs vs PBM Therapy post root canal (RCT)
  • ESWT vs PBM Therapy for Plantar Fasciitis (RCT)
  • Effect of PBM on cerebral hemodynamics and metabolism are not thermal
Posted in Research | Leave a comment

Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy

National Institute for Health and Care Excellence (NICE)
RESULT: After three presentations and much correspondence over a 5 year period we have a recommendation guideline from the National Institute of Health and Care Excellence (NICE) — LLLT for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This means the NHS can start using our treatment on cancer patients to reduce some of the painful side effects of cancer treatments.

Read here: https://www.nice.org.uk/guidance/ipg615

Posted in Industry | 1 Comment